Shamik J. Parikh - 21 Jan 2025 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Chief Medical Officer
Signature
/s/ Shamik J. Parikh by Dale A. Sander as Attorney-in-Fact
Issuer symbol
HUMA
Transactions as of
21 Jan 2025
Net transactions value
$0
Form type
4
Filing time
23 Jan 2025, 16:34:03 UTC
Previous filing
12 Dec 2023
Next filing
14 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +283,101 $0.000000 283,101 21 Jan 2025 Common Stock 283,101 $4.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.